Interim report
Page 1
Consolidated Financial Results for the Six Months Ended June 30 , 2026 ( Under Japanese GAAP ) Company name CREATE MEDIC CO . , LTD . Stock exchange listings : Tokyo Standard Securities code URL 5187 https://www.createmedic.co.jp/english/ FASF August 5 , 2026 Representative Inquiries Osamu Imazawa Teruya Ueno President Executive Officer , General Manager of Corporate Planning Department Semi - annual statement filing date ( as planned ) : August 10 , 2026 Dividend payable date ( as planned ) : September 8 , 2026 Supplemental material of results : Yes , only in Japanese Convening briefing of results : None ( Yen amounts are rounded down to millions , unless otherwise noted . ) 1. Consolidated financial results for the six months ended June 30 , 2026 ( from January 1 , 2026 to June 30 , 2026 ) ( 1 ) Consolidated operating results ( cumulative ) ( Percentages indicate year - on - year changes . ) Profit attributable to owners of parent Net sales Operating profit Ordinary profit Six months ended Millions of yen % June 30 , 2026 June 30 , 2025 6,932 6,564 5.6 4.2 Millions of yen 336 548 % Millions of yen % Millions of yen % ( 38.6 ) 88.3 398 ( 24.2 ) 260 ( 37.0 ) 525 51.8 412 ( 25.0 ) Note : Comprehensive income For the six months ended June 30 , 2026 For the six months ended June 30 , 2025 814 Millions of yen ( 157 ) Millions of yen ( - % ) ( - % ) Basic earnings per share Diluted earnings per share Six months ended June 30 , 2026 June 30 , 2025 Yen 31.63 48.35 Yen 28.46 ( 2 ) Consolidated financial position Total assets Net assets Capital adequacy ratio Net assets per share As of June 30 , 2026 December 31 , 2025 Millions of yen 20,140 20,143 Millions of yen 16,489 16.332 % 81.9 Yen 2,056.65 81.1 1,947.68 Reference : Owner's equity As of June 30 , 2026 As of December 31 , 2025 16,488 Millions of yen 16,331 Millions of yen 2. Cash dividends Annual dividend First quarter Second quarter Third quarter Year end Annual Yen Yen Yen Fiscal year ended December 31 , 2025 17.00 Yen 28.00 Yen 45.00 Fiscal year ending December 31 , 2026 20.00 Fiscal year ending December 31 , 2026 ( Forecast ) Note : Revisions to the forecast of cash dividends most recently announced : None - 1 - 27.00 47.00
Page 2
- 2 - 3. Consolidated financial forecast for the fiscal year ending December 31, 2026 (from January 1, 2026 to December 31, 2026) (Percentages indicate year-on-year changes.) Net sales Operating profit Ordinary profit Profit attributable to owners of parent Basic earnings per share Fiscal year ending Millions of yen % Millions of yen % Millions of yen % Millions of yen % Yen December 31, 2026 13,960 2.5 760 (24.4) 800 (19.0) 560 (21.5) 68.90 Note: Revisions to the earnings forecasts most recently announced：Yes * Notes (1) Significant changes in the scope of consolidation during the period：None (2) Adoption of accounting treatment specific to the preparation of semi-annual consolidated financial statements：None (3) Changes in accounting policies, changes in accounting estimates, and restatement (i) Changes in accounting policies due to revisions to accounting standards and other regulations ：None (ii) Changes in accounting policies due to other reasons ：None (iii) Changes in accounting estimates ：None (iv) Restatement ：None (4) Number of issued shares (common shares) ① Number of issued and outstanding shares at the period end (including treasury stock) As of June 30, 2026 9,664,327 shares As of December 31, 2025 9,664,327 shares ② Number of treasury stock at the period end As of June 30, 2026 1,647,294 shares As of December 31, 2025 1,279,220 shares ③ Average number of shares Six months ended June 30, 2026 8,223,275 shares Six months ended June 30, 2025 8,539,299 shares * Semi-annual financial results reports are exempt from review conducted by certified public accountants or an audit firm. * Proper use of earnings forecasts, and other special matters Caution Regarding Forward-Looking Statements: The forward-looking statements contained in this document are based on information currently available to the Company and certain assumptions that the Company deems to be reasonable. They are not intended as a promise by the Company that they will be achieved, and actual results may differ significantly due to various factors.